← All trials
NCT05417282
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2022
- Primary completion
- Dec 14, 2023
- Completion date
- Aug 14, 2024
- First posted
- Jun 14, 2022
- Last posted
- Jul 11, 2022
- Enrollment
- 40
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- ImmunoChem Therapeutics, LLCLead sponsor
- National Cancer Institute (NCI)Collaborator
- Northwestern UniversityCollaborator
- Northwestern UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.